Patent ID: 6432950
Filing Date: 2002-08-13
Classification: A61K

Abstract:
A method of treating a mammal having precancerous lesions comprising administering a pharmacologically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof: wherein R1 and R2 together form a C3-5 alkylene group; R3 and R4 are independently selected from the group consisting of hydrogen, A, â€”OA, halogen, â€”NO2, â€”NH2, â€”NHA or â€”NAAâ€², or R3 and R4 are together form a moiety selected from the group consisting of â€”Oâ€”CH2â€”CH2â€”, â€”Oâ€”CH2â€”Oâ€” or â€”CH2â€”CH2â€”O, X is selected from the group consisting of an unsubstituted or a substituted 5-7 membered saturated or unsaturated ring, wherein the ring is selected from the group consisting of phenyl, cyclopentyl, cyclohexyl, cycloheptyl, furyl, dioxolanyl, thienyl, pyrrolyl, pyrrolidinyl, imidazolyl, pyrazolyl, pyridyl, piperidinyl, morpholinyl, pyranyl, dioxanyl, pyridazinyl, pyrimidinyl, piperazinyl, quinolyl, and isoquinolyl and wherein the substituent on the â€œXâ€  ring are one or two selected from the group consisting ofâ€”lower alkyl, COOH, â€”COOA, â€”CONH2, â€”CONAAâ€², â€”CONHA, â€”CN, â€”CH2COOH or â€”CH2CH2COOH; A and Aâ€² are independently selected from the group consisting of C1-6 alkyl; and n is 0, 1, 2 or 3; and physiologically acceptable salts thereof.